Abhijit Chaudhuri, DM, MD, PhD, FACP, FRCP, FEAN, Queen's Hospital, Romford, UK, describes some of the controversies when treating neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody disease (MOGAD). In the NMOSD space, treatment selection and the costs of new interventions are two central controversies; choosing between conventional treatment with steroids or more recent and expensive strategies such as anti-CD20 or anti-CD19 antibodies. With MOGAD, the most extensive debate is regarding the duration of treatment and how effective it is to maintain treatment in serum-positive patients.
